While technological evolution is going on at every part of the world, healthcare is not far from this ongoing trend. From modern equipment to sophisticated software-enabled tools, healthcare is moving from clinics to people’s homes. Organizations like Biotricity, a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management, is creating an impact in the healthcare space.
Biotricity develops cutting-edge professional and personal remote medical monitoring technologies to enhance people’s lives. Biotricity is a modern medical technology company that focuses on providing medical and consumer markets with innovative, remote biometric monitoring solutions, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Bioflux by Biotricity is a single-unit, high-precision mobile cardiac telemetry (MCT) device that allows to monitor and transmit ambulatory patients’ ECG data in real-time. The Bioflux system is a complete remote cardiac monitoring solution that works with doctors’ existing platforms and processes. They monitor approximately 100 billion heartbeats each year in real-time by qualified cardiac technicians with unrivaled reporting capabilities.
By bridging the gap in remote monitoring and chronic care management, Biotricity is transforming the healthcare sector. Biotricity’s standard for preventative and personal care, including diagnostic and post-diagnostic treatments for chronic diseases, has earned the trust of doctors and patients alike. For the medical and consumer industries, the firm creates complete remote health monitoring systems. Biotricity’s Biocare Telemed is a virtual clinic platform that uses HIPAA-compliant technologies. The technology enables doctors to deliver excellent small patient care, allowing at-risk patients and those requiring remote cardiac monitoring to remain in the comfort of their own homes. The user-friendly platform guarantees that the platform is seamlessly integrated into the clinic’s present workflow, saving time and money. Biocare Pain Management by Biotricity is an interactive app that allows patients and clinicians to register and track regions of pain, pain levels, medicines, pain management, activity level, food, sleep, and feeling/mood to manage pain better.
Biotricity has announced the impending release of Biocare Cardiac, a personal cardiac health application for those diagnosed with or are at risk of heart disease. The Biocare Cardiac application, designed to work with Samsung’s Galaxy Watch4 series, continually records users’ daily activities and gives crucial information on the heart performance, enabling patients to understand better and manage other cardiac problems. The new software is intended to help patients in between doctor appointments by involving in lifestyle management activities that will aid the doctors in making diagnoses using daily medical data such as ECG, SpO2, heart rate, weight, and fitness and activity details. “Cardiovascular disease is the number one killer in the U.S. Millions of cardiac patients are living with cardiac disease with no insight into their condition,” says Dr. Waqaas Al-Siddiq, Founder & CEO. “We are very excited about the addition of the Biocare Cardiac application and Samsung’s new Galaxy Watch4 series with Google Wear OS to our offerings. They provide a powerful combination that will help cardiac patients take control of their condition.”
Another case study that shows Biotricity’s future goals is the company’s recent development of Biokit. This bundled home-use set includes a digital thermometer, a pulse oximeter, and a blood pressure cuff. All three devices are FDA-approved, wireless-capable, and part of the Biotricity ecosystem, an interconnectivity platform. This is the next phase in the Bioflux system’s growth, in which additional tools are completely integrated to provide a complete remote cardiac monitoring solution. The kit is currently in the last stages of manufacture before going on sale. The Company anticipates that each item in the equipment will be accessible to consumers in the first quarter of 2022. The business does not expect any more FDA filings prior to commercial launch because all devices have been FDA certified. “We created the Biokit to strengthen our long-term vision of supporting diagnosed cardiac patients throughout their cardiac health journey,” concludes Siddiq. “Biokit is a natural extension of our Bioflux cardiac-diagnostic offering. For patients with cardiac disease, a personal medical device kit is ideal for long term monitoring. After speaking with both patients and physicians, it was clear that a product like this was an immediate need. I am pleased with how quickly we have developed a solution to fulfill this customer feedback, which is a testament to the team here. The Biokit will expand our total addressable market with a tailored offering for the $18.4 billion-dollar North American portable medical device market1. With Bioflux and Biokit combined, Biotricity will soon offer a comprehensive cardiac diagnostics and management product line for effective, accurate, and economic long-term disease management.”